Tertiary lymphoid structures in cancer

Ectopic lymphoid aggregates, termed tertiary lymphoid structures (TLSs), are formed in numerous cancer types, and, with few exceptions, their presence is associated with superior prognosis and response to immunotherapy. In spite of their presumed importance, the triggers that lead to TLS formation i...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2022-01, Vol.375 (6576), p.eabf9419-eabf9419
Main Authors: Schumacher, Ton N, Thommen, Daniela S
Format: Article
Language:English
Subjects:
Adaptive Immunity
Aggregates
Animals
Antitumor activity
Autoimmune diseases
Autoimmunity
Cancer
Chronic infection
Composition
Feedback (Response)
Heterogeneity
Humans
Immune checkpoint
Immune Checkpoint Inhibitors
Immune response
Immune system
Immunity
Immunotherapy
Inflammatory diseases
Lymphocytes
Lymphocytes T
Lymphoid tissue
Macromolecules
Markers
Microenvironments
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Organs
Prognosis
Stimuli
Tertiary Lymphoid Structures - immunology
Tertiary Lymphoid Structures - pathology
Therapeutic applications
Therapeutic targets
Tissues
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ectopic lymphoid aggregates, termed tertiary lymphoid structures (TLSs), are formed in numerous cancer types, and, with few exceptions, their presence is associated with superior prognosis and response to immunotherapy. In spite of their presumed importance, the triggers that lead to TLS formation in cancer tissue and the contribution of these structures to intratumoral immune responses remain incompletely understood. Here, we discuss the present knowledge on TLSs in cancer, focusing on (i) the drivers of TLS formation, (ii) the function and contribution of TLSs to the antitumor immune response, and (iii) the potential of TLSs as therapeutic targets in human cancers.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.abf9419